论文部分内容阅读
目的探讨阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效。方法选取汉川市人民医院2014年4月—2016年3月收治的冠心病患者84例,随机分为Q组与Q+A组,各42例。Q组予以曲美他嗪治疗,Q+A组予以阿托伐他汀联合曲美他嗪治疗,两组患者均持续治疗8周。比较两组患者临床疗效、平板运动持续时间、心绞痛发作诱发时间、ST段下移1 mm时间、血脂指标〔总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)〕,观察两组患者不良反应发生情况。结果 Q+A组患者临床疗效优于Q组(P<0.05)。治疗前两组患者平板运动持续时间、心绞痛发作诱发时间、ST段下移1 mm时间比较,差异无统计学意义(P>0.05);治疗后Q+A组平板运动持续时间、心绞痛发作诱发时间、ST段下移1 mm时间长于Q组(P<0.05)。治疗前两组患者TC、LDL-C、TG、HDL-C水平比较,差异无统计学意义(P>0.05);治疗后Q+A组TC、LDL-C、TG水平低于Q组,HDL-C水平高于Q组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效确切,可有效改善患者血脂指标,控制心绞痛发作,改善患者心功能,且安全性高。
Objective To investigate the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease. Methods 84 patients with coronary heart disease admitted from April 2014 to March 2016 in Hanchuan People’s Hospital were randomly divided into Q group and Q + A group, with 42 cases in each group. Q group was treated with trimetazidine, Q + A group was treated with atorvastatin combined with trimetazidine, two groups of patients were treated for 8 weeks. The clinical efficacy, duration of treadmill exercise, duration of angina pectoris episode, time to ST-segment shift 1 mm, serum lipids (TC, LDL-C, triglyceride ), High-density lipoprotein cholesterol (HDL-C)〕, two groups of patients with adverse reactions were observed. Results The clinical efficacy of Q + A group was better than that of Q group (P <0.05). There was no significant difference between the two groups in the duration of treadmill exercise, the time of onset of angina pectoris and the time of 1 mm ST-down in the two groups (P> 0.05). The duration of treadmill exercise, duration of angina pectoris onset, , ST segment down 1 mm longer than the Q group (P <0.05). The levels of TC, LDL-C and TG in Q + A group were lower than those in Q group and HDL group (P> 0.05), but no significant difference was found between the two groups before treatment -C level was higher than Q group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Atorvastatin combined with trimetazidine treatment of coronary heart disease is clinically effective and can effectively improve the patient’s blood lipid indicators, control angina pectoris, improve patient’s cardiac function, and high safety.